BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
 | 
Oct 05, 2009
 |  BioCentury  |  Analyst Picks & Changes

Analysts Picks & Changes

Analysts Picks & Changes

Company Bank Analyst Coverage Opinion Wk chg 10/2 cls
Actelion Ltd. (SIX:ATLN) UBS Martin Wales Price target Sell -4% CHF 62.55
Wales raised his target to CHF57 from CHF54, noting strong near-term growth trends for Actelion's Tracleer bosentan, a dual endothelin receptor antagonist for pulmonary arterial hypertension (PAH). He said the company continues to penetrate the market of patients with PAH secondary to other conditions as well as increase price in the U.S. He raised his FY09 and FY10 EPS estimate to $3.71 and $4.22, respectively, from $3.38 and...

Read the full 534 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >